Ligand to Host Analyst Day on February 28th in New York City
January 24 2017 - 4:30PM
Business Wire
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) will
host an Analyst Day on Tuesday, February 28, 2017 from 10:00 a.m.
to 11:30 a.m. Eastern time (7:00 a.m. to 8:30 a.m. Pacific time) in
New York City.
Company presenters will include:
- John Higgins, Chief Executive
Officer
- Matt Foehr, President and Chief
Operating Officer
- Matt Korenberg, Chief Financial
Officer
- Roland Buelow, Ph.D., Vice President,
Antibody Technologies
The event will be webcast live and will be able to be accessed
at www.ligand.com. A replay of this webcast will be available for
90 days following the event. For more information or to reserve a
seat, please contact Ani Mikaelian at amikaelian@lhai.com.
About Ligand Pharmaceuticals
Ligand is a biopharmaceutical company focused on developing or
acquiring technologies that help pharmaceutical companies discover
and develop medicines. Our business model creates value for
stockholders by providing a diversified portfolio of biotech and
pharmaceutical product revenue streams that are supported by an
efficient and low corporate cost structure. Our goal is to offer
investors an opportunity to participate in the promise of the
biotech industry in a profitable, diversified and lower-risk
business than a typical biotech company. Our business model is
based on doing what we do best: drug discovery, early-stage drug
development, product reformulation and partnering. We partner with
other pharmaceutical companies to leverage what they do best
(late-stage development, regulatory management and
commercialization) to ultimately generate our revenue. Ligand’s
Captisol® platform technology is a patent-protected, chemically
modified cyclodextrin with a structure designed to optimize the
solubility and stability of drugs. OmniAb® is a patent-protected
transgenic animal platform used in the discovery of fully human
mono- and bispecific therapeutic antibodies. Ligand has established
multiple alliances, licenses and other business relationships with
the world's leading pharmaceutical companies including Novartis,
Amgen, Merck, Pfizer, Celgene, Gilead, Janssen, Baxter
International and Eli Lilly.
Follow Ligand on Twitter @Ligand_LGND.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170124006232/en/
Ligand Pharmaceuticals IncorporatedTodd Pettingill(858)
550-7500investors@ligand.com@Ligand_LGNDorLHABruce Voss(310)
691-7100bvoss@lhai.com
Ligand Pharmaceuticals (NASDAQ:LGND)
Historical Stock Chart
From Aug 2024 to Sep 2024
Ligand Pharmaceuticals (NASDAQ:LGND)
Historical Stock Chart
From Sep 2023 to Sep 2024